Atrix gets OK to expand Eligard line

Atrix Laboratories Inc. (Nasdaq: ATRX) has gained regulatory approval to sell its three-month dosage of Eligard, a prostate cancer drug, the Fort Collins company announced Wednesday.

The three-month timed-release product, called Eligard 22.5mg, is the second step in the Eligard product line. A one-month version, called Eligard 7.5mg, was approved by the U.S. Food and Drug Administration in January, and was launched into the marketplace in May. Eligard 22.5mg should reach market in the fall, said Danette Meyer, director of investor relations for the company.

Atrix is awaiting approval on a four-month Eligard 30mg product. The active ingredient in Eligard is…